GlaxoSmithKline S.A.E. (BIOC) Financial Statements
Annual financial statement highlights for GlaxoSmithKline S.A.E., in Egyptian pounds (EGP) covering fiscal years 2006–2025. Figures are updated weekly from EGX filings via TradingView.
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Total assets | Total debt | DPS |
|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | — | — | — |
| 2024 | — | — | — | — | — | — | — |
| 2023 | — | — | — | — | — | — | — |
| 2022 | — | — | — | — | — | — | — |
| 2021 | — | — | — | — | — | — | — |
| 2020 | — | — | — | — | — | — | — |
| 2019 | — | — | — | — | — | — | — |
| 2018 | 1.62B | 34.03M | 0.4075 | 182.31M | 2.04B | 0 | 0.50 |
| 2017 | 1.45B | 102.34M | 1.2255 | -516M | 1.93B | 44.96M | 0.50 |
| 2016 | 1.17B | -3.93M | -0.05 | 27.44M | 1.81B | 0 | 0.50 |
| 2015 | 1.01B | 69.11M | 0.83 | 150.14M | 1.77B | 0 | 0.50 |
| 2014 | 1.06B | 64.08M | 0.77 | 271.89M | 1.47B | 0 | 0.50 |
| 2013 | 1.04B | 76.76M | 0.92 | 263.53M | 1.39B | 0 | 0.75 |
| 2012 | 918.11M | 72.12M | 0.86 | 141.81M | 1.2B | 0 | 0.75 |
| 2011 | 865.67M | 85.1M | 1.01 | 58.46M | 1.2B | 0 | 0.75 |
| 2010 | 726.84M | 93.04M | — | 103.45M | 1.14B | 0 | 0.75 |
| 2009 | 666.95M | 28.89M | — | -1.09M | 1.11B | 0 | 0.45 |
| 2008 | 641.1M | 83.72M | — | 35.87M | 1.1B | 0 | 0.45 |
| 2007 | 583.7M | 89.6M | — | -8.91M | 994.22M | 0 | — |
| 2006 | 589.34M | 63.67M | — | -10M | 925.9M | 0 | — |
All figures in EGP. Source: company disclosures to the Egyptian Exchange via TradingView; updated weekly.